Energy Capitol Resources

Bio-Path Holdings is a clinical-stage biotechnology company focused on developing personalized nucleic acid cancer drugs using its proprietary DNAbilize™ technology. The platform enables the delivery of antisense DNA to target proteins that cause cancer, while minimizing toxicity. Its lead candidate, prexigebersen (BP1001), is currently in Phase 2 clinical trials for the treatment of acute myeloid leukemia (AML). The company's pipeline also includes programs targeting solid tumors and other hematological malignancies. Bio-Path's approach utilizes neutral lipid-based nanoparticles to deliver antisense oligonucleotides systemically. The company was originally known as Energy Capital Resources before transitioning into the life sciences sector via a reverse merger.